| Ticker: SUPG | 6450 Hollis Street | |
| Exchange: NASDAQ-National Market | Emeryville, California 94608 | |
| Industry: Manufacturing | (510) 655-1075 |
| Type of Shares: | Common Shares | Filing Date: | 1/22/96 | |
| U.S. Shares: | 3,500,000 | Offer Date: | 3/13/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $5.50 - $7.50 | |
| Primary Shares: | 3,500,000 | Offer Price: | $6.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.41 | |
| Offering Amount: | $22,750,000 | Selling: | ||
| Expenses: | $815,000 | Reallowance: | ||
| Shares Out After: | 16,279,227 |
| Manager | Tier | Phone |
| Paulson Investment Company, Inc. | Lead Manager | (503) 243-6000 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 3/31/95 | 12/31/95 | 12/31/94 | 12/31/95 | ||
| Revenue: | $0.17 | $0.01 | $0.10 | Assets: | $2.16 |
| Net Income: | -$3.64 | -$2.73 | -$2.50 | Liabilities: | $0.51 |
| EPS: | -$0.31 | -$0.22 | -$0.21 | Equity: | $1.65 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a pharmaceutical company dedicated to the development and rapid commercialization of products intended to treat life threatening diseases, particularly cancer and blood cell disorders, and other serious conditions such as obesity. SuperGen is developing its anticancer portfolio of five generic products and four enhanced or "supergeneric" products. The Company is also developing a group of proprietary blood cell disorder products for the treatment of anemia associated with chemotherapy, radiotherapy, renal failure and a plastic anemia. SuperGen's proprietary obesity pill, which has shown promise in early preclinical and animal studies for chronic genetic obesity, general obesity and Type II diabetes, is currently in Phase I/II clinical trials. |
| Use of Proceeds |
| The company expects to use the net proceeds of this offering as follows: approximately 65% to fund research and development, primarily for conducting Phase I/II clinical trials for blood cell disorder and obesity pill programs and to a lesser extent for its generic and supergeneric programs, approximately 5% for capital expenditures (including laboratory equipment, leasehold improvements, office furniture and equipment, computer equipment and software) and the balance for working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.